Sign in
CompletedPhase 3

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms

Key facts

Who runs it
Hoffmann-La Roche
Where
China16 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
100 people enrolled
Started
27 Oct 2024
Ended
8 May 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Baloxavir Marboxil
  • Oseltamivir
Record updated
27 April 2026

Who can take part

Age
1 year to 11 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • A participant who has a diagnosis of influenza virus infection and meets all the following conditions:; Fever ≥ 38°C (tympanic temperature) at screening; At least one of the respiratory symptoms of influenza virus infection
  • A rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) shows positive for influenza A/B, e.g., point-of-care/local laboratory results with use of nasal aspirate, throat swab, or nasal drip/droplet (or other appropriate sample)
  • The time interval between the onset of symptoms and screening is ≤ 48 hours
  • PCR (-) or antigen test (-) for severe acute respiratory virus-coronavirus 2 (SARS-CoV-2) using point-of-care/local laboratory test with nasal aspirate, throat swab, or nasal drip/droplet (or other appropriate sample)

Who cannot take part

  • Received systemic corticosteroid or immunosuppressive therapy
  • Immunization with a live/attenuated influenza vaccine in 2 weeks prior to randomization
  • A participant who received any medications with anti-flu effect such as baloxavir, peramivir, oseltamivir, zanamivir, favipiravir, arbidol, amantadine or traditional Chinese anti-influenza medicines within 30 days before screening
  • A participant who received an investigational or unapproved drug product within 30 days or 5 x the half-life before screening, whichever is longer
  • A participant having severe influenza virus infection symptoms requiring inpatient treatment
  • Primary immunodeficiency syndrome
  • History of organ transplantation
  • Human immunodeficiency virus (HIV) infection
  • Previous malignancy within the last 5 years or has an active cancer at any site
  • Diagnosed with or suspected SARS-CoV-2 infection, or close contacts of diagnosed or suspected SARS-CoV-2 infected patients
  • Severe underlying disease or condition potentially affecting study evaluation in the opinion of the investigator/sub-investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety of a single dose baloxavir marboxil compared with 5 days of oseltamivir administered twice a day (BID) in Chinese pediatric participants aged 1 to < 12 years with influenza symptoms.

The 2 groups in the trial

  • Baloxavir MarboxilTreatment being tested

    Participants will receive a single oral dose of baloxavir marboxil on Day 1 based on body weight.

  • OseltamivirExisting treatment, for comparison

    Participants will receive oseltamivir twice a day for 5 days based on body weight.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III, Randomized, Open-Label, Active-Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Patients 1 to <12 Years of Age With Influenza Symptoms
Record updated
27 April 2026